These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 11738344)

  • 1. In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones.
    Brook I; Elliott TB; Pryor HI; Sautter TE; Gnade BT; Thakar JH; Knudson GB
    Int J Antimicrob Agents; 2001 Dec; 18(6):559-62. PubMed ID: 11738344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial susceptibilities of 40 isolates of Bacillus anthracis isolated in Turkey.
    Esel D; Doganay M; Sumerkan B
    Int J Antimicrob Agents; 2003 Jul; 22(1):70-2. PubMed ID: 12842331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility of Bacillus anthracis to eleven antimicrobial agents including novel fluoroquinolones and a ketolide.
    Frean J; Klugman KP; Arntzen L; Bukofzer S
    J Antimicrob Chemother; 2003 Aug; 52(2):297-9. PubMed ID: 12865385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selection of Bacillus anthracis isolates resistant to antibiotics.
    Athamna A; Athamna M; Abu-Rashed N; Medlej B; Bast DJ; Rubinstein E
    J Antimicrob Chemother; 2004 Aug; 54(2):424-8. PubMed ID: 15205405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro susceptibility of Mycoplasma hominis clinical isolates to tetracyclines, quinolones and macrolides.
    Samra Z; Rosenberg S; Soffer Y
    Diagn Microbiol Infect Dis; 2002 Dec; 44(4):359-61. PubMed ID: 12543541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro development of resistance to ofloxacin and doxycycline in Bacillus anthracis Sterne.
    Choe CH; Bouhaouala SS; Brook I; Elliot TB; Knudson GB
    Antimicrob Agents Chemother; 2000 Jun; 44(6):1766. PubMed ID: 10896651
    [No Abstract]   [Full Text] [Related]  

  • 7. In vitro susceptibility of Bacillus anthracis to various antibacterial agents and their time-kill activity.
    Athamna A; Massalha M; Athamna M; Nura A; Medlej B; Ofek I; Bast D; Rubinstein E
    J Antimicrob Chemother; 2004 Feb; 53(2):247-51. PubMed ID: 14688054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
    Kosowska-Shick K; Credito K; Pankuch GA; Lin G; Bozdogan B; McGhee P; Dewasse B; Choi DR; Ryu JM; Appelbaum PC
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2064-71. PubMed ID: 16723567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro susceptibility of Chlamydia pecorum to macrolides, tetracyclines, quinolones and beta-lactam.
    Pudjiatmoko ; Fukushi H; Ochiai Y; Yamaguchi T; Hirai K
    Microbiol Immunol; 1998; 42(1):61-3. PubMed ID: 9525782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro susceptibility of quinolone-resistant Campylobacter jejuni to new macrolide antibiotics.
    Endtz HP; Broeren M; Mouton RP
    Eur J Clin Microbiol Infect Dis; 1993 Jan; 12(1):48-50. PubMed ID: 8462563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.
    Nagai K; Davies TA; Dewasse BE; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 2001 Sep; 48(3):365-74. PubMed ID: 11533001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis.
    Hoffner SE; Gezelius L; Olsson-Liljequist B
    J Antimicrob Chemother; 1997 Dec; 40(6):885-8. PubMed ID: 9462443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro synergy testing of macrolide-quinolone combinations against 41 clinical isolates of Legionella.
    Martin SJ; Pendland SL; Chen C; Schreckenberger P; Danziger LH
    Antimicrob Agents Chemother; 1996 Jun; 40(6):1419-21. PubMed ID: 8726012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of ABT-773 versus macrolides and quinolones against resistant respiratory tract pathogens.
    Dubois J; St -Pierre C
    Diagn Microbiol Infect Dis; 2001; 40(1-2):35-40. PubMed ID: 11448561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the effects of macrolides, amoxicillin, ceftriaxone, doxycycline, tobramycin and fluoroquinolones, on the production of pneumolysin by Streptococcus pneumoniae in vitro.
    Anderson R; Steel HC; Cockeran R; von Gottberg A; de Gouveia L; Klugman KP; Mitchell TJ; Feldman C
    J Antimicrob Chemother; 2007 Nov; 60(5):1155-8. PubMed ID: 17848373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro susceptibility of recent clinical isolates of Chlamydia trachomatis to macrolides and tetracyclines.
    Samra Z; Rosenberg S; Soffer Y; Dan M
    Diagn Microbiol Infect Dis; 2001 Mar; 39(3):177-9. PubMed ID: 11337185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial susceptibility of Bacillus anthracis strains from Hungary.
    Kreizinger Z; Sulyok KM; Makrai L; Rónai Z; Fodor L; Jánosi S; Gyuranecz M
    Acta Vet Hung; 2016 Jun; 64(2):141-7. PubMed ID: 27342086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of spores on the comparative efficacies of five antibiotics for treatment of Bacillus anthracis in an in vitro hollow fiber pharmacodynamic model.
    Louie A; VanScoy BD; Brown DL; Kulawy RW; Heine HS; Drusano GL
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1229-39. PubMed ID: 22155821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones.
    Wise R; Brenwald NP; Andrews JM; Boswell F
    J Antimicrob Chemother; 1997 Apr; 39(4):447-52. PubMed ID: 9145816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type II topoisomerase mutations in Bacillus anthracis associated with high-level fluoroquinolone resistance.
    Bast DJ; Athamna A; Duncan CL; de Azavedo JC; Low DE; Rahav G; Farrell D; Rubinstein E
    J Antimicrob Chemother; 2004 Jul; 54(1):90-4. PubMed ID: 15190035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.